Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2015

View Archived Issues

Alios Biopharma starts first-in-human study of HCV polymerase inhibitor AL-704

Novavax reports data from phase II trial of quadrivalent seasonal influenza vaccine

arGEN-X and University of Bern to develop ARGX-110-based combination therapies

University of Sydney to study Cymerus stem cells in heart disease models

Heptares to use MorphoSys antibody discovery technology against GPCR target

D-Pharm reports results from pilot trial of DP-b99 in acute pancreatitis

Filgotinib meets key efficacy endpoints in phase IIb DARWIN 1 study

Eisai and Halozyme sign collaboration agreement to investigate eribulin and PEGPH-20

Beijing Normal University patents technetium complexes for imaging

Coferon discloses Bcr-Abl tyrosine-kinase ligands

FDA accepts IND for EDO-S101 in patients with hematologic malignancies and solid tumors

KannaLife Sciences describes neuroprotectants

Aurigene Discovery Technologies divulges IRAK-4 inhibitors

KT&G Life Sciences develops NQO1 modulators

Alios Biopharma starts phase I drug interaction study for AL-335

AstraZeneca and Isis Pharmaceuticals form second antisense therapy collaboration

Sanofi profiles pipeline progress of second quarter 2015

Novel apelin receptor agonist shows promise as vasodilator

Perjeta regimen approved in E.U. for use before surgery in early-stage breast cancer

CTLA4-targeted therapies show promise for the treatment of LRBA deficiency

Allergan's AGN-223575 enters phase II study in dry eye

Biocad initiates phase I trial comparing adalimumab biosimilar to Humira

Anti-GD2 antibody enters phase II trial in osteosarcoma

TiGenix acquires Coretherapix

ORAI1 inhibitors show potential for the treatment of pancreatitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...